Cardiometabolic disease treatments and biotech innovation by Esperion Therapeutics
Short term diuretic strategy launched by Esperion Therapeutics ahead of IV escalation
Esperion Therapeutics has announced the availability of a short term option for managing diuretic therapy in patients with heart failure before the need for intravenous escalation. This new ...
Esperion Therapeutics pursues collaborative efforts to advance cardiovascular care
Esperion Therapeutics positions collaboration as a key factor in advancing cardiovascular healthcare. The company acknowledges that every stakeholder contribution is vital in making progress ...
Esperion Therapeutics prioritizes excellence at all stages of pharmaceutical development
Esperion Therapeutics affirms that quality is fundamental across all aspects of its operations. The company states that its dedication to excellence underpins each stage of development, aiming ...
Esperion Therapeutics commends Ryan Hudson for contributions to employee initiatives
Esperion Therapeutics recognized Ryan Hudson this week for his dedication, expertise, and positive impact within the organization. The company expressed gratitude for Hudson’s ongoing ...
ACC app from Esperion Therapeutics integrates patient data for tailored cholesterol management
Esperion Therapeutics has introduced an updated ACC Lipid Manager app aimed at guiding clinicians through the lipid-lowering process by integrating two essential tools: Lipid Lowering Therapy and ...
Esperion Therapeutics launches recruitment drive to advance cardiovascular care
Esperion Therapeutics has announced an active hiring campaign aimed at enhancing its position in the field of cardiovascular care. The company is encouraging candidates to explore new employment ...
New pediatric cholesterol study data released by Esperion Therapeutics at European Atherosclerosis Society event
Esperion Therapeutics unveiled data from its CLEAR Outcomes trial and the CLEAR PATH Phase 2 pediatric study at the European Atherosclerosis Society Congress 2026. The presentations focused on ...
Esperion Therapeutics estimates U.S. heart failure costs at 46B dollars a year, urges therapy optimization
Esperion Therapeutics estimates the annual economic burden of heart failure in the U.S. at 46 billion dollars, encompassing healthcare services, medications, and lost productivity. The company ...
